RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Applied Therapeutics Stock

Applied Therapeutics P/E 2024

Applied Therapeutics P/E

-3.21

Ticker

APLT

ISIN

US03828A1016

WKN

A2PHHB

As of Sep 29, 2024, Applied Therapeutics's P/E ratio was -3.21, a 252.75% change from the -0.91 P/E ratio recorded in the previous year.

The Applied Therapeutics P/E history

Applied Therapeutics Aktienanalyse

What does Applied Therapeutics do?

Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for chronic and specific serious diseases. The company was founded in 2016 by Shoshana Shendelman, who is also the CEO of the company. Applied Therapeutics is headquartered in New York City and currently employs over 50 employees. The business model of Applied Therapeutics is designed to address gaps in current medical care and develop novel therapies that do not yet exist. The company invests heavily in research and development to find new drugs and therapies that are more effective and safer than existing treatment methods. Applied Therapeutics has focused on developing drugs that can be used in the areas of neurological and cardiovascular diseases, as well as metabolic diseases. The main products currently under development aim to treat metabolic diseases such as diabetic neuropathy and mucopolysaccharidosis (MPS). The company has a broad portfolio of technologies, including the targeted protein degrader platform, which aims to degrade critical proteins that play a role in certain diseases. Applied Therapeutics also uses genomics to gain a deeper understanding of the underlying causes of diseases. By identifying targets for new drugs and therapies, the company also uses AI algorithms to select promising candidates for clinical trials. Applied Therapeutics' particular expertise lies in the research of molecules that play a key role in regulating carbohydrate metabolism and energy production in the body. Applied Therapeutics' medications aim to selectively regulate these critical molecules and thus combat various diseases. The first product from Applied Therapeutics is AT-001, a medication for the treatment of diabetic neuropathies. A phase II study has shown that AT-001 provides a significant improvement in neuropathic pain and sensitivity. The medication is currently being tested in a phase III clinical trial. Another promising class of drugs from Applied Therapeutics is the SGLT2 inhibitor, which targets carbohydrate metabolism and thus covers a wide range of diseases, from diabetes to cardiovascular diseases. Applied Therapeutics has also signed a license agreement with the University of Minnesota for the development of medications for the treatment of MPS I. In this collaboration, the company brings its expertise in molecules regulating carbohydrate and energy metabolism to develop a new treatment for MPS patients. It is important to mention that Applied Therapeutics' drugs are still in development and are in various stages of clinical trials. After completing the clinical trials and potential FDA approval, the products must also be brought to market, which can pose additional challenges. Overall, Applied Therapeutics has focused on developing therapies for chronic and serious diseases. The company has a broad portfolio of technologies aimed at combating the underlying causes of diseases. With AT-001 already on the market, the company has brought a promising medication to market, and additional products are in development. Whether the company will meet its ambitious goals remains to be seen, but there is no doubt that it operates in an exciting area with great potential. Applied Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Applied Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Applied Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Applied Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Applied Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Applied Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Applied Therapeutics stock

What is the price-to-earnings ratio of Applied Therapeutics?

The price-earnings ratio of Applied Therapeutics is currently -3.21.

How has the price-earnings ratio of Applied Therapeutics changed compared to last year?

The price-to-earnings ratio of Applied Therapeutics has increased by 252.75% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Applied Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Applied Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Applied Therapeutics affect the company?

An increase in the price-earnings ratio of Applied Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Applied Therapeutics affect the company?

A decrease in the price-earnings ratio of Applied Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Applied Therapeutics?

Some factors that influence the price-earnings ratio of Applied Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Applied Therapeutics pay?

Over the past 12 months, Applied Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Applied Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Applied Therapeutics?

The current dividend yield of Applied Therapeutics is .

When does Applied Therapeutics pay dividends?

Applied Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Applied Therapeutics?

Applied Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Applied Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Applied Therapeutics located?

Applied Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Applied Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Applied Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Applied Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Applied Therapeutics in the year 2023?

In the year 2023, Applied Therapeutics distributed 0 USD as dividends.

In which currency does Applied Therapeutics pay out the dividend?

The dividends of Applied Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Applied Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Applied Therapeutics

Our stock analysis for Applied Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.